Sticky Overzicht van nootropics

MeDieViL · 2 dec 2012

Amphetamine is the best nootropic, serieus voordat ik stims gebruike was ik totaal geen expert over deze materie, op amp hebbek zoveel geleerd het is gwn indrukwekkend (srry als dit nergens op slaat ben wat van de kaart)

MeDieViL · 2 dec 2012

Damn die coluracetam is goeie shit, een van de nieuwe dingen die ik wil gaan verkopen

tunux · 2 dec 2012

MeDieViL zei:
Damn die coluracetam is goeie shit, een van de nieuwe dingen die ik wil gaan verkopen

Maar jij woont toch in England? hoe wil je het dan hierheen versturen?

Marter · 2 dec 2012

met de post ;-)

Marter · 2 dec 2012

MeDieViL zei:
Damn die coluracetam is goeie shit, een van de nieuwe dingen die ik wil gaan verkopen

Al ergens te koop? Gebruikservaringen?

MeDieViL · 2 dec 2012

Marter zei:
Al ergens te koop? Gebruikservaringen?

nope, was custom synthed door iemand en een select longevity members kregen een exclusief sample:
http://www.longecity.org/forum/topic/58609-coluracetam-user-feedback/

---------- Post toegevoegd Sun 2 Dec 2012 om 20:48 ----------

BRAINCELLS INC. ANNOUNCES RESULTS FROM EXPLORATORY PHASE 2A TRIAL OF BCI-540 [COLURACETAM] IN DEPRESSION WITH ANXIETY

Positive Signal Observed in Difficult-to-Treat Patient Population

SAN DIEGO, Calif., June 14, 2010 – BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel compounds for the treatment of central nervous system (CNS) diseases, announced today findings from an exploratory, dose ranging Phase 2a clinical trial not powered for statistical significance. The trial evaluated BCI-540 [COLURACETAM] for the treatment of patients with major depressive disorder (MDD) with anxiety who had previously failed an average of two antidepressants. While there was no difference between the overall treatment group and placebo on scales for depression and anxiety, further analysis showed a positive efficacy signal in a subset of patients with MDD and general anxiety disorder (GAD), which warrants further study.

“Co-morbid depression and anxiety remains a significant unmet need, representing approximately 40 percent of depressed patients. BCI-540 [COLURACETAM] elicited a stronger response in this group of patients, providing us direction for additional studies to better understand its therapeutic potential,” said Allan Young, MB, ChB, Ph.D., FRCPsych, FRCPC, director of the Institute of Mental Health at the University of British Columbia and lead investigator of the trial. “I look forward to its next step in development.”

The six-week trial was randomized, double-blind and placebo-controlled to determine whether 80 milligrams of BCI-540 [COLURACETAM] dosed orally once or three times daily (TID) improves symptoms in patients with MDD and anxiety who had previously failed an average of two antidepressants. The trial measured change from baseline at week two, four and six for 101 evaluable patients with a variety of commonly used patient and physician-rated scales including the Hamilton Rating Scales for Anxiety (HAM-A) and Depression (HAM-D).

At week six, in the overall population there was no benefit of BCI-540 [COLURACETAM] on HAM-A or HAM-D compared to placebo. However, in patients who were dosed TID, 36% responded compared to 19% in the placebo group. Within this group, depression symptoms of those with co-morbid GAD improved by 12.2 points on HAM-D compared to 5.5 points in the placebo group (p<0.008). BCI-540 [COLURACETAM] was well tolerated, with a side effect profile similar to placebo.

“Neurogenesis is an exciting new field that is demonstrating potential in many different CNS diseases including depression and anxiety,” said Carrolee Barlow, M.D., Ph.D., chief scientific and medical officer at BrainCells. “BCI-540 [COLURACETAM] began to separate from placebo by four weeks, which is in line with our understanding of how neurogenesis progresses in the brain. It is an important clinical finding that we’ll take forward as we investigate the therapeutic opportunity of BCI-540 [COLURACETAM] in this difficult-to-treat population.”

BCI-540 [COLURACETAM] is a bifunctional molecule that works to treat mood disorders through two mechanisms of action, AMPA potentiation and choline uptake enhancement. BrainCells identified through its platform the compound’s ability to help new neurons differentiate and survive, two important aspects of the neurogenesis process. Experiments conducted by BrainCells confirmed appropriate changes in behavioral models for depression, without affecting serotonin levels, potentially eliminating side effects typically associated with selective serotonin reuptake inhibitors (SSRIs) like Prozac. Currently, only 30 to 40 percent of people with depression fully respond to current treatments.

---------- Post toegevoegd Sun 2 Dec 2012 om 20:52 ----------

Zulke exclusieve shit ga ik verkopen, de competitie gaat geen kans maken, met mijn kennis, ook heb ik massas argumenten waarom een bank mij een lening zou geven voor mijn business, de competitie is makkelijk te verslaan en het is een growing market. (zoals hier niemand had intresse, ik promp intresse en heb massas potentiele customers, ik bereid het rustig voor om zeker te zijn dat het een succes word

tunux · 2 dec 2012

MeDieViL zei:
nope, was custom synthed door iemand en een select longevity members kregen een exclusief sample:
http://www.longecity.org/forum/topic/58609-coluracetam-user-feedback/

---------- Post toegevoegd Sun 2 Dec 2012 om 20:48 ----------

BRAINCELLS INC. ANNOUNCES RESULTS FROM EXPLORATORY PHASE 2A TRIAL OF BCI-540 [COLURACETAM] IN DEPRESSION WITH ANXIETY

Positive Signal Observed in Difficult-to-Treat Patient Population

SAN DIEGO, Calif., June 14, 2010 – BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel compounds for the treatment of central nervous system (CNS) diseases, announced today findings from an exploratory, dose ranging Phase 2a clinical trial not powered for statistical significance. The trial evaluated BCI-540 [COLURACETAM] for the treatment of patients with major depressive disorder (MDD) with anxiety who had previously failed an average of two antidepressants. While there was no difference between the overall treatment group and placebo on scales for depression and anxiety, further analysis showed a positive efficacy signal in a subset of patients with MDD and general anxiety disorder (GAD), which warrants further study.

“Co-morbid depression and anxiety remains a significant unmet need, representing approximately 40 percent of depressed patients. BCI-540 [COLURACETAM] elicited a stronger response in this group of patients, providing us direction for additional studies to better understand its therapeutic potential,” said Allan Young, MB, ChB, Ph.D., FRCPsych, FRCPC, director of the Institute of Mental Health at the University of British Columbia and lead investigator of the trial. “I look forward to its next step in development.”

The six-week trial was randomized, double-blind and placebo-controlled to determine whether 80 milligrams of BCI-540 [COLURACETAM] dosed orally once or three times daily (TID) improves symptoms in patients with MDD and anxiety who had previously failed an average of two antidepressants. The trial measured change from baseline at week two, four and six for 101 evaluable patients with a variety of commonly used patient and physician-rated scales including the Hamilton Rating Scales for Anxiety (HAM-A) and Depression (HAM-D).

At week six, in the overall population there was no benefit of BCI-540 [COLURACETAM] on HAM-A or HAM-D compared to placebo. However, in patients who were dosed TID, 36% responded compared to 19% in the placebo group. Within this group, depression symptoms of those with co-morbid GAD improved by 12.2 points on HAM-D compared to 5.5 points in the placebo group (p<0.008). BCI-540 [COLURACETAM] was well tolerated, with a side effect profile similar to placebo.

“Neurogenesis is an exciting new field that is demonstrating potential in many different CNS diseases including depression and anxiety,” said Carrolee Barlow, M.D., Ph.D., chief scientific and medical officer at BrainCells. “BCI-540 [COLURACETAM] began to separate from placebo by four weeks, which is in line with our understanding of how neurogenesis progresses in the brain. It is an important clinical finding that we’ll take forward as we investigate the therapeutic opportunity of BCI-540 [COLURACETAM] in this difficult-to-treat population.”

BCI-540 [COLURACETAM] is a bifunctional molecule that works to treat mood disorders through two mechanisms of action, AMPA potentiation and choline uptake enhancement. BrainCells identified through its platform the compound’s ability to help new neurons differentiate and survive, two important aspects of the neurogenesis process. Experiments conducted by BrainCells confirmed appropriate changes in behavioral models for depression, without affecting serotonin levels, potentially eliminating side effects typically associated with selective serotonin reuptake inhibitors (SSRIs) like Prozac. Currently, only 30 to 40 percent of people with depression fully respond to current treatments.

---------- Post toegevoegd Sun 2 Dec 2012 om 20:52 ----------

Zulke exclusieve shit ga ik verkopen, de competitie gaat geen kans maken, met mijn kennis, ook heb ik massas argumenten waarom een bank mij een lening zou geven voor mijn business, de competitie is makkelijk te verslaan en het is een growing market. (zoals hier niemand had intresse, ik promp intresse en heb massas potentiele customers, ik bereid het rustig voor om zeker te zijn dat het een succes word

Zoe doe je dat

MeDieViL · 2 dec 2012

Paar jaar terug had ik totaal geen kennis over nix, all thx to amphetamine.

Paul Erdös
LIFE ON BENZEDRINE

Jewish Hungarian mathematician Paul Erdös
Paul Erdös (1913-1996), "the man who loved only numbers", was one of the most brilliant and prolific mathematicians of the twentieth century. Erdös spent much of his restless life on psychostimulants. As he once remarked, "A mathematician is a device for turning coffee into theorems." [some sources attribute the original quote to Erdös' friend and fellow Hungarian mathematican Alfréd Rényi.]
But Erdös liked stronger medicine too. After his mother's death in 1971, Erdös became quite depressed. His physician prescribed amphetamines. Erdös took Benzedrine or Ritalin almost every day for the last twenty five years of his life. Sometimes he took both.

Long-term use of amphetamines often exacerbates depression. When used chronically, too, amphetamines usually induce stereotyped thought and behaviour rather than creativity. But Paul Erdös seems to be an exception. He felt living on speed helped him to create maths. At an age when most mathematicians have long since burnt out, his output was certainly prodigious.

Strong dopaminergic drugs also tend to provoke or exacerbate obsessive-compulsive behaviour. Here their effect on Erdös may be more typical. Erdös hated to be touched; and he washed his hands some 50 times a day.

Colleagues worried that Erdös might have become addicted. In 1979, he accepted a $500 bet from his friend Ronald Graham. Graham challenged Erdös to abstain from speed for 30 days. Erdös met the challenge, but his output sank dramatically. Erdös felt the progress of mathematics had been held up by a stupid wager.

In an article by Paul Hoffman published in November 1987, Atlantic Monthly profiled Erdös and discussed his Benzedrine habit. Erdös liked the article, "...except for one thing...You shouldn't have mentioned the stuff about Benzedrine. It's not that you got it wrong. It's just that I don't want kids who are thinking about going into mathematics to think that they have to take drugs to succeed."

Daster · 2 dec 2012

Heb je hier nou zo'n grote lening voor nodig dan. Je werkt toch gewoon vanuit huis met een webshopje

Tythor Zeth · 2 dec 2012

Daster zei:
Heb je hier nou zo'n grote lening voor nodig dan. Je werkt toch gewoon vanuit huis met een webshopje

Ik denk dat hij het groots wilt aanpakken

MeDieViL · 2 dec 2012

Absoluut, wil de competitie zo snel mogenlijk van de kaart vegen

X. · 2 dec 2012

Als je een korting geeft koop ik wel bij je.

Tythor Zeth · 2 dec 2012

markrot zei:
Als je een korting geeft koop ik wel bij je.

Korting voor je DBB broeders

MeDieViL · 3 dec 2012

Offcourse, en de beste prijzen offcourse youll order with me anyway.

---------- Post toegevoegd Mon 3 Dec 2012 om 01:21 ----------

Als het genoeg een succes word kan ik sommige dingen met verlies verkopen speciaal om de competitie van de kaart te vegen.

rickynl · 3 dec 2012

MeDieViL zei:
Offcourse, en de beste prijzen offcourse youll order with me anyway.

---------- Post toegevoegd Mon 3 Dec 2012 om 01:21 ----------

Als het genoeg een succes word kan ik sommige dingen met verlies verkopen speciaal om de competitie van de kaart te vegen.

Als je daarna ons maar niet extra gaat laten betalen

MeDieViL · 3 dec 2012

Haha offcourse not

Ano_1991_32 · 3 dec 2012

MeDieViL zei:
Paar jaar terug had ik totaal geen kennis over nix, all thx to amphetamine.

Welke stack zou jij aanraden bij gebruik van ritalin? (heb ADD) Qua noots dan. Thx

Jorin · 3 dec 2012

Demian zei:
Waar bewaren jullie je nootropics in? Hoe scheppen jullie het? scoop? Hoe nemen jullie het in?

Ik heb atm mn nootropics in van die grote dichtseal zakjes met zon rand die je in elkaar clickt zodat het luchtdicht zit. Leg het op een (speel)kaart en die hou ik boven mn mond om het in mn mond te schuiven en dan klok ik het weg met water.

Vroeg me af hoe jullie dit doen

Demian serieus. Soms vraag ik me echt af of jij niet slightly retarded bent. Je hebt het mij denk al een paar keer gevraagd, en ik heb het in dit topic ook al een paar keer gezet.

voor de laatste keer nu dan, speciaal voor jou.

1) 2 VLOEITJES pakken, je tong naar buiten steken.
2) Tong langs plakrand van vloeitje halen.
3) LIKKEN.
4) Andere vloeitje pakken en aan de ander vastplakken.
5) Theelepel afstrijken (om en nabij de 1 gram).
6) Troep er in gooien en bommetje van maken.

Heb voor jou ook al de tussenstappen gepost, zodat je niet in de war raakt.

xxx

jor

Musculo · 3 dec 2012

MeDieViL zei:
Offcourse, en de beste prijzen offcourse youll order with me anyway.

---------- Post toegevoegd Mon 3 Dec 2012 om 01:21 ----------

Als het genoeg een succes word kan ik sommige dingen met verlies verkopen speciaal om de competitie van de kaart te vegen.

Zat je aan de amp tijdens deze post?

MeDieViL · 3 dec 2012

Musculo zei:
Zat je aan de amp tijdens deze post?

Yep maar ik zeg dit ook without

Sticky Overzicht van nootropics

Monstrous Giant

Monstrous Giant

Ripped Bodybuilder

Ripped Bodybuilder

Ripped Bodybuilder

Monstrous Giant

Ripped Bodybuilder

Monstrous Giant

Monstrous Giant

Freaky Bodybuilder

Monstrous Giant

Freaky Bodybuilder

Freaky Bodybuilder

Monstrous Giant

Competitive Bodybuilder

Monstrous Giant

Competitive Bodybuilder

Freaky Bodybuilder

Adolescent bodybuilder

Monstrous Giant

Soortgelijke topics